A Phase IIa Study of RItuximab and VArlilumab in Relapsed or Refractory B-cell Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Rituximab (Primary) ; Varlilumab (Primary)
- Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms RiVa
- 06 Feb 2018 Status changed from not yet recruiting to recruiting.
- 18 Aug 2017 New trial record
- 16 Aug 2017 Status changed from not yet recruiting to recruiting.